FAKTOR-OPTIONSSCHEIN - GENMAB | Real-time Boerse Frankfurt Warrants 02:35:41 17/06/2024 pm IST | ||
| 11.46 EUR | +4.85% |
|
| Current month | +11.87% | ||
| 1 month | +18.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 11.46 | +4.85% |
| 14/24/14 | 10.93 | -1.71% |
| 13/24/13 | 11.12 | +2.30% |
| 12/24/12 | 10.87 | +5.74% |
| 11/24/11 | 10.28 | +2.39% |
Real-time Boerse Frankfurt Warrants
Last update June 17, 2024 at 02:35 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW9NAT |
| ISIN | DE000SW9NAT5 |
| Date issued | 29/04/2024 |
| Strike | 1,916 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.13 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.46 € |
|---|---|
| Lowest since issue | 8.76 € |
| Spread | 0.03 € |
| Spread % | 0.26% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,832
DKK
Average target price
2,464
DKK
Spread / Average Target
+34.46%
- Stock Market
- Certificates
- Certificat
